Researchers from Biotica, UK have discovered a new compound class called sangamides with the potential to treat hepatitis C. Sangamides are amide derivatives of sanglifehrin A – a cyclophilin-binding polyketide natural product. Non-immunosuppressive analogues of sanglifehrin A are currently under development as hepatitis C virus therapies, but suffer from lengthy synthetic processes, and some adverse affects including drug-drug interactions.
The newly developed sangamides display improved potency and good pharmcokinetic properties that make them potentially suitable for once-a-day oral treatment of chronic hepatitis C infection. Download the article for the full details:
Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infection
Steven J. Moss, Michael Bobardt, Pieter Leyssen, Nigel Coates, Udayan Chatterji, Xie Dejian, Teresa Foster, Jinlun Liu, Mohammad Nur-e-Alam, Dipen Suthar, Chen Yongsheng, Tony Warneck, Ming-Qiang Zhang, Johan Neyts, Philippe Gallay, Barrie Wilkinson and Matthew A. Gregory
Med. Chem. Commun., 2012, Advance Article
DOI: 10.1039/C1MD00227A
